EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chronic kidney disease outcomes in patients treated with immune checkpoint inhibitors

Nabil Abu-Amer iD, Amir Givon, Nirit Agay, Havi Murad, Noi Horesh, Margarita Kunin, Orit Erman, Adva Vaisman, Haim Mayan, Pazit Beckerman, Ronen Loebstein

Clinical Kidney Journal · 31.07.2026 · 19 (8)

DOI: 10.1093/ckj/sfag224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 11.07.2026. Verfasst von Nabil Abu-Amer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nephrology and Hypertension, Sheba Medical Center, Tel Hashomer, Israel. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sheba Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) are increasingly used in oncology, but long-term kidney outcomes in patients with pre-existing CKD (chronic kidney disease) are not well understood. We assessed CKD progression in patients with a baseline eGFR of 15–60 ml/min/1.73 m² who were treated with ICIs, comparing outcomes with those receiving chemotherapy.

Methods

We conducted a retrospective cohort study at Sheba Medical Center between 2015 and 2024. The primary outcome was a composite of new-onset end-stage kidney disease, initiation of kidney replacement therapy, or a >30% eGFR decline for at least 90 days. The secondary outcome was time to the first composite event. We used a Cox model with time-varying exposure and a propensity score-matched, new-user active comparator analysis to minimize selection bias.

Results

Of 3468 patients treated with ICIs, 885 had a baseline of eGFR 15–60 ml/min/1.73 m²; 208 met the inclusion criteria for CKD progression analysis. The composite outcome occurred in 22% of patients, with a shorter time-to-event in CKD stage 4 than in CKD stage 3 (27 vs. 83 months; P = 0.003). Factors associated with CKD progression included hydronephrosis (HR 5.6), smoking (HR 2.09), higher eosinophil counts (HR 4.8), and higher baseline creatinine (HR 3.0). Higher hemoglobin reduced the risk by 12%. ICI exposure was not associated with an increased risk compared with chemotherapy in the time-varying analysis (HR 0.83) or the matched active comparator (HR 0.81). These findings remained consistent in sensitivity analyses excluding patients with genitourinary malignancies.

Conclusions

Among patients with eGFR 15–60 ml/min/1.73 m², systemic anticancer therapy carries a substantial risk of renal decline; however, ICIs do not increase the risk of CKD progression compared to chemotherapy. Outcomes are predominantly driven by baseline renal impairment and individual risk factors, highlighting the necessity of close renal monitoring rather than avoiding ICIs in this vulnerable population.

Schlagwörter

Stichwörter der Autor:innen

ESKDcancerchemotherapychronic kidney diseaseimmune checkpoint inhibitors

Autor:innen und Institutionen

  • Institute of Nephrology and Hypertension, Sheba Medical Center, Tel Hashomer, Israel.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel.
  • Biostatistics & Biomathematics Unit, Data & Analytics Division, Sheba Medical Center, Tel Hashomer, Israel.
  • Department of Internal medicine C, Sheba Medical Center, Tel Hashomer, Israel.

ORCID-Profile: Nabil Abu-Amer

Förderung

  • Sheba Medical Center

Zitieren

APA

Abu-Amer, N., Givon, A., Agay, N., Murad, H., Horesh, N., Kunin, M., Erman, O., Vaisman, A., Mayan, H., Beckerman, P., & Loebstein, R. (2026). Chronic kidney disease outcomes in patients treated with immune checkpoint inhibitors. Clinical Kidney Journal, 19(8). https://doi.org/10.1093/ckj/sfag224

Vancouver

Abu-Amer N, Givon A, Agay N, Murad H, Horesh N, Kunin M, et al. Chronic kidney disease outcomes in patients treated with immune checkpoint inhibitors. Clinical Kidney Journal. 2026;19(8). doi:10.1093/ckj/sfag224

BibTeX
@article{AbuAmer2026,
  author = {Abu-Amer, Nabil and Givon, Amir and Agay, Nirit and Murad, Havi and Horesh, Noi and Kunin, Margarita and Erman, Orit and Vaisman, Adva and Mayan, Haim and Beckerman, Pazit and Loebstein, Ronen},
  title = {Chronic kidney disease outcomes in patients treated with immune checkpoint inhibitors},
  journal = {Clinical Kidney Journal},
  year = {2026},
  volume = {19},
  number = {8},
  doi = {10.1093/ckj/sfag224}
}
Kostenlos starten →